で公開中です！詳しく見る

Novartis

NVS

時価総額 $2863億

150.62 USD

+0.24

0.16%

終値時点更新済み 10月16日 16:00 EDT

プレマーケット

時間外取引

148.40

-2.22

1.47%

1日

0.16%

5日間

4.71%

1か月

8.59%

3か月

-1.38%

6か月

0.59%

年初来

8.72%

1年

15.18%

5年間

82.92%

10年間

122.42%

概要： Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.

従業員数： 75,267

ヘルスケア医薬品メーカー（総合）

ニュース

ポジティブ

ニュートラル

ネガティブ

センチメント 3か月間

ポジティブ 35.8%

ニュートラル 18.9%

ネガティブ 45.3%

ネガティブ

Novartis ends mid-stage Fabhalta trial targeting serious kidney condition

Swiss drugmaker Novartis has terminated a mid-stage study testing its drug Fabhalta in patients with a ‌serious kidney condition, citing "strategic considerations", according to a federal clinical trials registry.

Novartis ends mid-stage Fabhalta trial targeting serious kidney condition

ニュートラル

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novartis AG ("Novartis" or the "Company") (NYSE: NVS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

ニュートラル

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Novartis AG (“Novartis” or the “Company”) (NYSE: NVS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

ポジティブ

Zacks Investment Research

NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido

Novartis wins FDA approval for Rhapsido in symptomatic dermographism, expanding its chronic hives opportunity as pipeline setbacks raise pressure for growth.

NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido

ニュートラル

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novartis AG ("Novartis" or the "Company") (NYSE: NVS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

ポジティブ

US FDA expands use of Novartis drug for chronic skin condition

The US Food and Drug Administration has expanded the use of Novartis' drug to treat adults with a chronic skin condition that causes recurring itchy welts, ‌the Swiss drugmaker said on Wednesday.

US FDA expands use of Novartis drug for chronic skin condition

ニュートラル

Focus: AI companies run virtual drug trials, aim to improve success of human studies

Novartis' experimental del-desiran for a rare type of muscular dystrophy was expected to be a winner, with the Swiss company's CEO predicting annual peak sales of $5 billion. When a late-stage trial missed its goal last month, shares fell 11%, erasing $30 billion in market value.

Focus: AI companies run virtual drug trials, aim to improve success of human studies

ニュートラル

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Novartis AG (“Novartis” or the “Company”) (NYSE: NVS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

ポジティブ

Zacks Investment Research

Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal

NVS gains global rights to Abogen's ABO2203, expanding its RNA therapeutics push with a potential new approach to B-cell-mediated autoimmune diseases.

Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal

ポジティブ

Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals

Swiss Novartis is entering a licensing agreement with a Chinese biotech worth as much as $7.8 billion. It comes after several pharma peers announced deals with China-based drug developers over the past two weeks.

Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals

ニュースランキングを見る

価格チャートは Lightweight Charts™ を使用して実装されています